Molecular imaging biomarkers for immune checkpoint inhibitor therapy.

ABSTRACT: Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with ¹⁸F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of

SUBMITTER: van de Donk PP 

PROVIDER: S-EPMC6993216 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature